2025. 8. Xilio Therapeutics (XLO) 100x or die

Xilio Therapeutics (XLO): Small Biotech with Big Potential?

Xilio’s the next 100x rocket!!! unless it explodes

What’s their deal?

Xilio is developing tumor-selective immunotherapies. Simply put, their drugs only “turn on” inside tumors, not in healthy tissue. This could mean fewer side effects and stronger cancer-fighting power.

AbbVie and Gilead are both involved

1. AbbVie signed a research deal with Xilio to co-develop a masked TNF (tumor necrosis factor) program. TNF is powerful against cancer but usually too toxic; Xilio’s tech could make it safer and more effective.
2. Gilead Sciences not only is interested in Xilio’s tumor microenvironment (TME) targeting technology, but also invested directly in the company. Gilead has been actively expanding its oncology footprint, and their investment signals strong confidence in Xilio’s approach.

What’s in their pipeline?

1. XTX101: Tumor-activated anti-CTLA-4 antibody in clinical trials
2. XTX202: Tumor-selective IL-2 therapy
3. XTX301: Targets TGFβR2, an immune-suppressing protein in tumors
4. Plus the AbbVie-partnered masked TNF program

All are designed to activate only inside tumors—minimizing damage to healthy cells.

Is it still undervalued?

Xilio’s market cap is still under $100 million. For a company with clinical-stage assets, and two pharma giants both collaborating and investing? That’s rare.

Bottom line:

1. 🎯 Tumor-selective immunotherapy = safer, smarter cancer drugs
2. 🤝 AbbVie collaboration on masked TNF
3. 💰 Gilead both invested in and interested in Xilio
4. 🧬 Multiple clinical programs in progress
5. 📉 Market cap still tiny = big room to grow
6. ⚠️ High risk, but big reward potential

No financial advice — just my personal take. I threw down $5,000.

Caution:

I’m just throwing out stock picks that feel right. 

No promises, No refunds. Don’t blame me if your wallet cries! HAHAHAHA